Am J Transplant, Volume 21, Suppl 3 Archives - Page 18 of 139 - ATC Abstracts

2021 American Transplant Congress
Donor-Derived Cell-Free DNA as a Surrogate Marker for “Allograft Quiescence” After Kidney Transplantation
J. S. Bromberg¹, L. Bu², G. Gupta³, I. Moinuddin³, S. Anand⁴, A. Pai⁵, T. Alhamad⁶, V. Bowers⁷, S. Ghosh⁸, W. Tian⁸, E. Stites⁹
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Minnesota, Minneapolis, MN, ³Virginia Commonwealth University, Richmond, VA, ⁴Intermountain Medical Center, Murray, UT, ⁵University of Texas McGovern Medical School, Houston, TX, ⁶Washington University in St. Louis, St. Louis, MO, ⁷Tampa General Hospital, Tampa, FL, ⁸CareDx, Brisbane, CA, ⁹University of Colorado, Aurora, CO
*Purpose: Donor-derived cell-free DNA (dd-cfDNA; AlloSure®) and the association with active rejection (AR) was described by Bloom et al, however subsequent insights have suggested this…
2021 American Transplant Congress
Impact of Social Support, Social Circumstances and Distance from Transplant Center on Post Liver Transplant Outcomes: An Analysis from a Predominantly Rural U.S. Cohort
R. Kaur¹, C. Lavender¹, E. Askew¹, S. Jafri², R. Thandassery¹, M. Deneke¹
¹University of Arkansas for Medical Sciences, Little Rock, AR, ²Henry Ford Hospital, Detroit, MI
*Purpose: Social support and social circumstances (SSSC) are critical yet less described entities in post-orthotopic liver transplant (OLT). We aimed to describe SSSC and correlate…
2021 American Transplant Congress
Identification of Molecular Markers for Liver Cirrhosis by Single-nucleus Rna Sequencing
C. Kuscu¹, C. Kuscu¹, M. Akram², A. Shetty³, D. G. Maluf⁴, J. Eason¹, V. Mas⁵
¹Surgery, James D Eason Transplat Institute, Memphis, TN, ²Surgery, Center for Biomedical Informatics, Memphis, TN, ³Surgery, Institute for Genome Sciences, School of Medicine, Baltimore, MD, ⁴Surgery, Program in Transplantation University of Maryland, Baltimore, MD, ⁵Surgery, Division of Surgical Science University of Maryland, Baltimore, MD
*Purpose: Non-alcoholic fatty liver disease (NAFLD) is characterized by metabolic syndrome and the accumulation of fat in the liver cells (hepatocytes) leading to inflammation and…
2021 American Transplant Congress
Regional Trends in Liver Transplantation for Nonalcoholic Steatohepatitis
C. L. Hanlon¹, B. Saberi², L. Yuan¹
¹Internal Medicine, University of Southern California, Los Angeles, CA, ²Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: This study aims to evaluate regional trends in liver transplantation (LT) among adults in the United States (US) with nonalcoholic steatohepatitis (NASH), with particular…
2021 American Transplant Congress
Liver Transplantation Following Checkpoint Inhibitor Therapy – Timing is Everything
G. T. Schnickel¹, J. Parekh¹, Y. Kono², J. Berumen¹, V. Ajmeera², K. Mekeel¹
¹Division of Transplant and Hepatobiliary Surgery, Department of Surgery, University of California San Diego, San Diego, CA, ²Division of Gastroenterology, Department of Medicine, University of California San Diego, San Diego, CA
*Purpose: Use of checkpoint inhibitors (CPI) prior to liver transplantation has not been well studied and limited case reports describe a risk of early graft…
2021 American Transplant Congress
Utilization of Pre-Procurement Donor Liver Biopsy in Donation-after-circulatory-Death Liver Transplantation
A. C. Bolognese¹, N. Neidlinger¹, C. Sparks², A. Schneider², A. M. D'Alessandro¹, D. P. Foley¹
¹Department of Surgery, Division of Transplantation, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW Organ and Tissue Donation, Madison, WI
*Purpose: Careful selection of suitable DCD donor livers is critical to obtain optimal transplant outcomes. In order to identify potentially suitable livers prior to DCD…
2021 American Transplant Congress
The Survival Benefits of Using Marginal Allografts in Liver Transplantation
T. H. Malik¹, E. L. Godfrey¹, A. Rana²
¹Baylor College of Medicine, Houston, TX, ²Department of Abdominal Transplantation, Baylor College of Medicine, Houston, TX
*Purpose: Our study assessed whether using marginal allografts at initial time of listing provided similar or greater survival benefit versus waiting on the transplant waitlist…
2021 American Transplant Congress
Portal Vein Challenges in Pediatric Liver Transplantation: The Utility of Interposition Grafts as an Acceptable Management Strategy
R. Hogen, K. Etesami, J. Cervantes, Y. Kwon, S. Zielsdorf, J. Emamaullee, Y. Genyk
Division of Hepatobiliary and Abdominal Organ Transplantation, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA
*Purpose: To examine our single center experience in the operative management of pediatric liver transplantation (LT) patients with challenging portal vein (PV) anomalies.*Methods: We retrospectively…
2021 American Transplant Congress
Application of Linear Discriminant Analysis (lda) to Differentiate Acute Rejection (ar) and Acute Dysfunction Non-Rejection (adnr) in Liver Transplant Recipients
M. Miller¹, R. Sinha¹, J. Weems¹, J. Holman², M. Altrich¹, S. Kleiboeker¹, J. Levitsky³
¹R&D, Viracor-Eurofins, Lee's Summit, MO, ²Transplant Genomics, Mansfield, MA, ³R&D, Northwestern University Feinberg School of Medicine, Chicago, IL
*Purpose: Blood-based biomarkers distinguishing acute-rejection (AR) from other causes of graft dysfunction (acute dysfunction non-rejection (ADNR)) would have significant clinical applicability in liver transplant (LT)…
2021 American Transplant Congress
Mortality from Fulminant Myocarditis in Multi-organ Transplant Recipient with Covid-19
K. Mahendraraj, I. Kim, T. Todo, T. Brennan, N. Nissen, K. Kosari, G. Voidonikolas, D. Ramzy
Transplant Surgery, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Novel coronavirus infection has been rarely described in multi-organ transplantation. This case highlights the poor prognosis associated with cardiac involvement by SARS-Cov-2 in transplantation,…